Announcements Trials
Browse Landscape

Phase

Phase 2 74Phase 3 43Phase 1 43Phase 1/2 39Phase NA 5Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Trimethoprim, Sulfamethoxazole Drug Combination 4Thalidomide 4Cyclophosphamide 4gamma-Globulins 3Ciprofloxacin 3carfilzomib 2Melphalan 2Immunoglobulins, Intravenous 2Calcium Dobesilate 2Amoxicillin-Potassium Clavulanate Combination 2trametinib 1tanespimycin 1pomalidomide 1pazopanib 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Radiotherapy 1Radiation 1Pharmaceutical Preparations 1Mesna 1MAGEA3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × pomalidomide × Plasma cell × Clear all
NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Peking University People's Hospital

Phase 2/3 Recruiting
202 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡